Infectious Disease Point Of Care Diagnostics Market Overview
The Infectious Disease Point Of Care Diagnostics Market is expanding as healthcare providers increasingly adopt rapid diagnostic solutions for timely detection and management of infectious diseases. Rising infectious disease prevalence, growing demand for rapid testing, technological advancements, increasing healthcare expenditure, and the shift toward decentralized diagnostics are supporting market growth.
According to the WiseGuyReports market report published on December 24, 2025, the global Infectious Disease Point Of Care Diagnostics Market was valued at USD 5 Billion in 2024 and is projected to grow from USD 5.4 Billion in 2025 to USD 10.5 Billion by 2035, registering a CAGR of 6.9% during 2025–2035. North America held the largest regional position, valued at USD 1.656 Billion in 2024 and projected to reach USD 3.402 Billion by 2035. Molecular Diagnostics was the leading test type, valued at USD 2.4 Billion in 2024 and projected to reach USD 4.6 Billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=618122
Key players driving innovation and competitiveness in the Infectious Disease Point Of Care Diagnostics Market include:
Nanjing Sike Biomedical Technology
BioRad Laboratories
Abbott Laboratories
Quidel Corporation
Thermo Fisher Scientific
Hologic
Roche Diagnostics
BD
Siemens Healthineers
Danaher Corporation
Mylab Discovery Solutions
Cepheid
The market is being shaped by the growing need for rapid and accessible infectious disease testing across hospitals, laboratories, urgent care centers, and home-care settings. Advances in molecular diagnostics, artificial intelligence, machine learning, microfluidics, and portable testing technologies are improving diagnostic speed, accuracy, and accessibility. The increasing focus on early diagnosis and decentralized testing is also creating new opportunities for point-of-care solutions.
The Infectious Disease Point Of Care Diagnostics Market can be segmented by Test Type into Molecular Diagnostics, Immunodiagnostics, and Others. By Application, it includes HIV Testing, Hepatitis Testing, Tuberculosis Testing, and Malaria Testing. By End Use, it covers Hospitals, Diagnostic Laboratories, Home Care, and Urgent Care Centers. By Product Type, it includes Assay Kits, Instruments, Software, and Consumables. Regionally, the market covers North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
The growing need for accessible and efficient infectious disease testing is creating opportunities for diagnostic manufacturers, healthcare providers, laboratories, biotechnology companies, and digital health technology developers. Portable testing devices, AI-enabled diagnostics, microfluidic platforms, telehealth integration, and decentralized testing solutions can support market differentiation and future growth.
Recent Developments and Market Trends:
Molecular diagnostics are gaining importance because of their ability to provide rapid and precise detection of infectious diseases.
Artificial intelligence and machine learning are increasingly being integrated into diagnostic platforms to improve analytical speed, accuracy, and interpretation.
The shift toward decentralized testing is increasing demand for portable and user-friendly point-of-care diagnostic devices.
Microfluidics technology is supporting the development of compact diagnostic systems that can deliver rapid results with lower resource requirements.
Telehealth integration is creating opportunities to connect point-of-care diagnostics with remote healthcare and monitoring services.
Growing healthcare investments and infectious disease preparedness initiatives are supporting the expansion of rapid diagnostic infrastructure across emerging markets.
Reasons to Buy the Report:
Provides comprehensive insights into the Infectious Disease Point Of Care Diagnostics Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across molecular diagnostics, immunodiagnostics, and other point-of-care testing technologies.
Offers detailed segmentation analysis across test type, application, end use, product type, and geographic markets.
Includes competitive intelligence covering leading diagnostic, biotechnology, healthcare technology, and medical-device companies.
Supports informed decisions using market forecasts, infectious disease trends, rapid testing demand, technological advancements, decentralized healthcare adoption, and regional opportunities.
Future Outlook:
The future of the Infectious Disease Point Of Care Diagnostics Market will be shaped by rising infectious disease prevalence, growing demand for rapid diagnosis, technological advancements, decentralized testing, healthcare infrastructure investments, and increasing focus on early disease detection. Molecular Diagnostics is expected to remain a major test type, with the segment projected to increase from USD 2.4 Billion in 2024 to USD 4.6 Billion by 2035. North America is expected to retain its leading regional position, with the market projected to grow from USD 1.656 Billion in 2024 to USD 3.402 Billion by 2035. Asia Pacific is positioned for significant growth as healthcare access, diagnostic infrastructure, and demand for rapid testing increase. The global Infectious Disease Point Of Care Diagnostics Market is projected to reach USD 10.5 Billion by 2035 at a CAGR of 6.9%.
➤➤Explore Our Latest Related Reports:
